Epithelial Ovarian CancerPlatinOvNCT03954171
Platino-resistance in Ovarian Cancer
A study testing Patients treated with platinum based-chemotherapy in people with Epithelial Ovarian Cancer, run by Institut Claudius Regaud at 1 site in France.
Trial summary
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Epithelial Ovarian Cancer
- What is being tested?
- Patients treated with platinum based-chemotherapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 1 siteFrance
- Study dates
- 6 Mar 2020to Mar 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years old
- Epithelial ovarian cancer at initial diagnosis (all stages)
- Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
- Indication of platinum based-chemotherapy
- Patient affiliated to the french social security system
- Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure
Who cannot join
- Non-epithelial ovarian tumor, borderline ovarian tumor
- Patient with recurrent disease
- Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)"
- Pregnant or breastfeeding women
- Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse
Gwenaël FERRON, 05 31 15 53 55, Ferron.Gwenael@iuct-oncopole.fr
About this study
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).
Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.
Read more
A prospective database and an associated biological collection will be performed during 5 years:
- For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care.
- Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).
Study participation of each patient will be 5 years.
- Conditions
- Epithelial Ovarian Cancer
- Being tested
- Patients treated with platinum based-chemotherapy
- Keywords
- Epithelial Ovarian Cancer, Platinum based-chemotherapy
- Medical subject headings
- Carcinoma, Ovarian Epithelial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patients treated with platinum based-chemotherapyOther
Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):
- before treatment initiation (blood sample),
- during hospitalisation for surgery (blood sample),
- during follow-up consultations (blood sample).
If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.
| Study group | Role | What they receive |
|---|---|---|
| Patients treated with platinum based-chemotherapy | Other | Not described Receives: Other: Patients treated with platinum based-chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of patients alive without progression
Measured: 5 years for each patient
Secondary outcomes (1)
The time to onset of platinum based-chemotherapy resistance
Measured: 5 years for each patient
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2019
- Study start6 Mar 2020
- Primary completionMar 2033 (estimated)
- Study completionMar 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epithelial Ovarian CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Claudius Regaud
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03954171
- Sponsor's protocol ID
- 19 GENF 01
- Acronym
- PlatinOv
- Status last verified
- Nov 2025
- First submitted
- 15 May 2019
- Last updated
- 18 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Platino-resistance in Ovarian Cancer
- ClinicalTrials.gov ID
- NCT03954171
- Acronym / sponsor ID
- PlatinOv / 19 GENF 01
- Conditions
- Epithelial Ovarian Cancer
- Keywords
- Epithelial Ovarian Cancer, Platinum based-chemotherapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Institut Claudius RegaudUniversity, hospital or other
- Study start
- 6 Mar 2020 (actual)
- Primary completion
- Mar 2033 (estimated)
- Study completion
- Mar 2033 (estimated)
- First posted
- 17 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).
Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.
A prospective database and an associated biological collection will be performed during 5 years:
- For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care.
- Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).
Study participation of each patient will be 5 years.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients treated with platinum based-chemotherapy | Other | Other: Patients treated with platinum based-chemotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years old
- Epithelial ovarian cancer at initial diagnosis (all stages)
- Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
- Indication of platinum based-chemotherapy
- Patient affiliated to the french social security system
Key exclusion criteria (6 listed)
- Non-epithelial ovarian tumor, borderline ovarian tumor
- Patient with recurrent disease
- Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)"
- Pregnant or breastfeeding women
- Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patients treated with platinum based-chemotherapyBlood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice): * before treatment initiation (blood sample), * during hospitalisation for surgery (blood sample), * during follow-up consultations (blood sample). If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study. | Other | Patients treated with platinum based-chemotherapy |
Primary outcome
The rate of patients alive without progression
Time frame: 5 years for each patient
1 secondary outcome
The time to onset of platinum based-chemotherapy resistance
Time frame: 5 years for each patient
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
Related trials for Epithelial Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 3
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patients treated with platinum based-chemotherapy in people with Epithelial Ovarian Cancer, run by Institut Claudius Regaud at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gwenaël FERRON (05 31 15 53 55, Ferron.Gwenael@iuct-oncopole.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of patients alive without progression (time frame: 5 years for each patient). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.